The Center for Cancer Drug Development (C2D2)

癌症药物开发中心 (C2D2)

• 批准号: 6831011
• 负责人: STEPHEN B HOWELL
• 金额: $ 7.6万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-05 至 2006-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6831011
• 关键词: antineoplastics; biomedical resource; cooperative study; drug design /synthesis /production; drug discovery /isolation; drug screening /evaluation; pharmacokinetics

DESCRIPTION (provided by applicant): The goal of this application is to plan for the development of an AP4 Center at the University of California, San Diego. The Center for Cancer Drug Development (C2D2) will be established at the Rebecca and John Moores UCSD Cancer Center to exploit enormously powerful new genomic, genetic, molecular, and computational tools to accelerate the development of novel cancer therapeutics, diagnostics, and molecular imaging techniques. Investigators at UCSD have identified a myriad of potential drug targets, drugs, and novel computational imaging and diagnostic technologies that are of interest to numerous pharmaceutical companies. The research program of the C2D2 will be focused on the use of new biomedical tools and the information they generate to accelerate completion of the critical preclinical steps required to advance these potential therapeutics toward commercial development. The C2D2 expects to make available to partners not only fundamental genomic and genetic information that support the rationale for potential therapeutics, but also novel drugs, imaging technology and diagnostics for their consideration for further development. Major areas of research interest include: identification of multigenic complex genetic host determinants that predict the probability of response and outcome, and that influence the toxicity of cancer drugs; novel molecular imaging technology for functional assessment of tumors and drug effect; novel techniques for tumor-specific drug delivery; identification and exploitation of kinase pathways uniquely activated in chronic lymphocytic leukemia cells; the biology of tumor neovasculature and the development of novel anti-angiogenic agents; new computational and informatics tools to identify drug targets and assess drug effect; and, new strategies for antibody-based treatment of acute leukemia.

描述(由申请人提供)： 这个应用程序的目标是计划在加州大学圣地亚哥分校开发一个AP4中心。癌症药物开发中心(C2D2)将在丽贝卡和约翰摩尔斯加州大学圣迭戈分校癌症中心建立，以利用极其强大的新基因组、遗传学、分子和计算工具来加速新型癌症治疗、诊断和分子成像技术的发展。加州大学圣迭戈分校的研究人员已经确定了许多制药公司感兴趣的无数潜在的药物靶点、药物和新颖的计算成像和诊断技术。C2D2的研究计划将侧重于使用新的生物医学工具及其产生的信息，以加快完成将这些潜在疗法推向商业开发所需的关键临床前步骤。C2D2希望向合作伙伴提供的不仅是支持潜在疗法基本原理的基本基因组和遗传信息，还包括新药、成像技术和诊断，供他们考虑进一步开发。主要研究领域包括：预测应答概率和结局并影响抗癌药物毒性的多基因复杂遗传宿主决定因素的识别；用于肿瘤功能评估和药物效应的新的分子成像技术；肿瘤特异性给药的新技术；识别和开发慢性淋巴细胞白血病细胞中独特激活的激酶通路；肿瘤新生血管的生物学和新型抗血管生成药物的开发；识别药物靶点和评估药物效果的新的计算和信息学工具；以及基于抗体的急性白血病治疗的新策略。